Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
7 February 2022 |
Main ID: |
NCT02021695 |
Date of registration:
|
22/11/2013 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes
|
Scientific title:
|
DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes |
Date of first enrolment:
|
September 2013 |
Target sample size:
|
249 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT02021695 |
Study type:
|
Observational |
Study design:
|
|
Phase:
|
|
|
Countries of recruitment
|
Qatar
| | | | | | | |
Contacts
|
Name:
|
Charbel Abi Khalil, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Weill Cornell Medical College in Qatar |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
1. Must provide informed consent
2. Males or Females aged 30 years or older to minimize the potential confounding of other
forms of diabetes mellitus
3. In patients with diabetes, no concomitant diseases except for micro- and macrovascular
complications of diabetes (nephropathy, retinopathy, peripheral arterial disease,
coronary artery disease, neuropathy) or symptoms of the metabolic syndrome
(hypertension, dyslipidemia and obesity)
4. Not taking any chronic medications (except of the diabetes and cardiovascular related
drugs).
Exclusion Criteria:
1. Diagnosis of Type-I Diabetes
2. Active situational diabetes (steroids use/pregnancy)
3. Active infection or acute illness of any kind
4. Chronic inflammation (auto-immune diseases) or infection
5. Evidence of malignancy within the past 5 years
6. Chronic hematological disorders known to affect glycated hemoglobin results such as
hemoglobinopathies (e.g. sickle cell disease and thalassemia), increases red-cell
turnover (e.g. hemolytic anemia and spherocytosis.
- Evidence of malignancy within the past 5 years
- Chronic hematological disorders known to affect glycated hemoglobin results such
as hemoglobinopathies
Age minimum:
30 Years
Age maximum:
N/A
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Type 2 Diabetes
|
Primary Outcome(s)
|
DNA methylation and gene expression in blood monocytes and lymphocytes
[Time Frame: 1 hour]
|
Secondary ID(s)
|
13-00023 [JIRB]
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|